The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).
 
Megan Crumbaker
Honoraria - Bayer; Merck
Consulting or Advisory Role - Astellas Pharma; Pfizer
Travel, Accommodations, Expenses - MSD Oncology
 
Laurence Krieger
Honoraria - Astellas Pharma; AstraZeneca (Inst); Bayer; Bristol-Myers Squibb (Inst); Ipsen; Janssen; Merck
Consulting or Advisory Role - AstraZeneca; Bayer; Ipsen; Janssen; Merck; MSD
Speakers' Bureau - Bayer; Ipsen; MSD
Research Funding - AstraZeneca; Bayer; BeiGene (Inst); Exelixis; MSD
 
David Pook
Honoraria - Bayer; Bayer; Merck/Pfizer
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; Bayer; Bristol Myers Squibb Foundation; Bristol-Myers Squibb; Bristol-Myers Squibb; Cipla; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Merck/Pfizer; Merck/Pfizer; Pfizer; Pfizer (Inst)
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Merck/Pfizer; Merck/Pfizer; MSD; Pfizer; Pfizer
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Antoinette Fontela
No Relationships to Disclose
 
Christopher Oldmeadow
No Relationships to Disclose
 
Josh Hurwitz
Honoraria - Merck
Travel, Accommodations, Expenses - Novartis
Other Relationship - Gilead Sciences; Pfizer
(OPTIONAL) Uncompensated Relationships - Eisai
 
Andrisha Inderjeeth
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Pfizer
 
Haryana Dhillon
No Relationships to Disclose
 
Teesha Downton
No Relationships to Disclose
 
Gavin Marx
No Relationships to Disclose
 
Samantha Shekar
No Relationships to Disclose
 
Emmanuel Antonarakis
Consulting or Advisory Role - AADi; AIkido Pharma; Amgen; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Corcept Therapeutics; Curium Pharma; Foundation Medicine; Hookipa Pharma; Janssen Biotech; Lilly; Menarini Silicon Biosystems; Merck; Pfizer; Sanofi; Tango Therapeutics; Tempus; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Merck (Inst); Orion Health (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
 
Samuel Denmeade
Research Funding - Astellas Pharma (Inst); Bayer
Patents, Royalties, Other Intellectual Property - Patent licensed to Pfizer receive patent maintenance fees
 
Angelyn Anton
Honoraria - Bayer; Janssen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Janssen (Inst); MSD (Inst); Mundipharma (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Janssen
 
Thean Tan
No Relationships to Disclose
 
Sharad Sharma
No Relationships to Disclose
 
Jeffrey Goh
Stock and Other Ownership Interests - ICON Cancer Care
Honoraria - MSD Oncology
Consulting or Advisory Role - Abbvie; Eisai; GlaxoSmithKline; MSD
Speakers' Bureau - AstraZeneca/MedImmune; Eisai; Janssen; MSD Oncology
Travel, Accommodations, Expenses - Bayer
 
Lisa Horvath
Employment - Connected Medical Solutions (I)
Leadership - ANZUP; Connected Medical Solutions (I)
Stock and Other Ownership Interests - Connected Medical Solutions (I); Imagion Biosystems
Honoraria - ANZUP; Astellas Pharma; Bayer; Janssen
Consulting or Advisory Role - Astellas Pharma; Bayer; Imagion Biosystems
Research Funding - Astellas Pharma
Patents, Royalties, Other Intellectual Property - Provisional patent Australian No. 2022902527 Prognostic Markers (plasma lipid prognostic signature in metastatic prostate cancer). Inventors: Horvath L, Meikle P, Scheinberg S, Lin HM, Sullivan D The patent is owned by the Chris O'Brien Lifehouse (my (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; MSD Oncology; Pfizer
 
Anthony Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Mayne Pharma (Inst); Medison (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Myeloid Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods
 
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
No Relationships to Disclose